Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma

Recruiting now

Conditions studied: Myeloma Multiple

In brief

This project will evaluate the efficacy and safety of the conditioning regimen bortezomib-bendamustine-melphalan (BBM) in combination with autologous hematopoietic stem cell transplantation (ASCT) in relapsed multiple myeloma given from 2011 to 2018 at Uppsala University Hospital. This approach will be retrospectively compared to high dose melphalan (HDM) in the same setting in the years prior to, and following the BBM-period. Data on efficacy and safety data will be collected through systematic analysis of electronic medical records and from the Swedish Cancer Registry.

Key facts

Study ID

NCT06245629

Run by

Uppsala University

People needed

100

Starts

2024-11-24

Expected to finish

2025-11-30

Last updated by the study team

2024-11-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of first relapse after previous ASCT for multiple myeloma according to the International Myeloma Working Group.
• Treated with a second ASCT (ASCT2) as part of second line treatment at UUH.
• Conditioning at ASCT2 with bortezomib-bendamustine-melphalan or high-dose melphalan only.

You may not qualify if…

• Double (tandem) ASCT in first or second line treatment
• Allogenic haematopoietic stem cell transplantation as part of first or second line therapy
• Failure to meet the minimal dataset, defined as: (date of ASCT1 and ASCT2, date of start of induction treatment for relapsed myeloma prior to ASCT2, medical records from hospitalization for ASCT2, at least one follow-up visit (unless early death before first follow-up visit), date of progression and first treatment of relapsed multiple myeloma after ASCT2.

Where it is running

• Akademiska sjukhuset — Uppsala, Sweden (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.